Navigation Links
Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine
Date:2/22/2010

ROCKVILLE, Md., Feb. 23 /PRNewswire/ -- Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The three-year award totaling approximately $3 million will support collaborative research by investigators at Sanaria and Columbia University. This new funding extends previous NIAID supported efforts at Sanaria and Columbia to develop genetically modified strains of the human malaria parasite Plasmodium falciparum that are unable to cause disease, yet stimulate protective immunity when administered as a live, whole parasite malaria vaccine. "There is considerable excitement about whole parasite malaria vaccines, and research towards developing genetically modified strains for such vaccines is at the cutting edge of this field," states Dr. Christian Loucq, Director of the PATH Malaria Vaccine Initiative.

Sporozoite stage parasites that have been weakened (attenuated) by exposure to radiation confer high-level protection against malaria when introduced by the bite of infected mosquitoes. The attenuated parasites invade host tissues, but cannot complete differentiation and therefore do not replicate or cause disease. Sanaria has developed technologies and built a facility to manufacture a radiation attenuated sporozoite vaccine that can be administered by injection and has met FDA regulatory standards for initial clinical evaluation.  This vaccine candidate, the SanariaTM PfSPZ Vaccine, is now being assessed in clinical trials. According to Dr. Stephen L. Hoffman, Sanaria's founder and chief scientist, "Sanaria is uniquely positioned at this time to expand the pipeline of candidate sporozoite vaccines to include vaccines based on precisely gene-altered parasites that are highly potent in inducing protective immunity against malaria and are unable to cause disease."

"Sanaria's proven ability to manufacture whole sporozoite vaccines in compliance with FDA standards means that promising new strains of the malaria parasite that are being developed in our research laboratory can be efficiently translated into prototype candidate vaccines suitable for testing in the clinic," says Dr. David Fidock of Columbia University. Dr. Robert Sauerwein of the Radboud University Nijmegen Medical Centre, whose laboratory in collaboration with Sanaria has generated several genetically attenuated strains of Plasmodium falciparum concurs, stating, "This is a very exciting opportunity to make significant strides that will facilitate translation from the laboratory to clinical studies of a vialed, genetically attenuated, sporozoite vaccine inoculated by needle and syringe."  

About Sanaria Inc.

Sanaria Inc. was founded in 2003.  The company's primary mission is to develop and commercialize attenuated whole-parasite malaria vaccines that confer high-level, long-lasting protection against Plasmodium falciparum, the parasite responsible for most of the malaria-associated severe illness and death worldwide. Sanaria's radiation attenuated sporozoite vaccine, SanariaTM PfSPZ Vaccine, entered clinical trials in 2009. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The company's Web site is http://www.sanaria.com.

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements.

For further information contact:
Media- Adam Richman 301.770.3222, Investors- Robert Thompson 240.403.2750

SOURCE Sanaria Inc.

Back to top

RELATED LINKS
http://www.sanaria.com

'/>"/>

SOURCE Sanaria Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
2. Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
3. UH Superconductivity Center Receives Texas Emerging Technology Fund Award
4. EUCODIS Bioscience Receives EUR 2 Million Cash Injection to Enlarge Product Portfolio and Develop International Markets
5. UC Riverside graphene specialist Jeanie Lau receives national honor at White House
6. Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
7. Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
8. BioCrysts Partner Shionogi Receives Marketing & Manufacturing Approval For Peramivir in Japan
9. Fibrocell Science, Inc. Receives FDA Complete Response Letter Regarding azficel-T for Wrinkles
10. Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreichs Ataxia Preclinical Development Program
11. Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program ... in Volunteer Experience from US2020. , US2020’s mission is to change the trajectory ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... , ... October 09, 2017 , ... ... four-tiered line of medical marijuana products targeting the needs of consumers who are ... of Kindred takes place in Phoenix, Arizona. , As operators of two successful ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ( ... online age and identity verification solutions, announced today they ... Conference 2017, May 15 thru May 17, 2017, in ... and International Trade Center. Identity impacts ... and in today,s quickly evolving digital world, defining identity ...
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
Breaking Biology News(10 mins):